Literature DB >> 9091694

Magnitude and duration of the effect of sepsis on survival. Department of Veterans Affairs Systemic Sepsis Cooperative Studies Group.

A A Quartin1, R M Schein, D H Kett, P N Peduzzi.   

Abstract

OBJECTIVE: To determine the magnitude and duration of the effects of sepsis on survival.
DESIGN: Cohort study.
SETTING: The 10 Department of Veterans Affairs Medical Centers of the Systemic Sepsis Cooperative Studies Group, which from 1983 to 1986 conducted the Department of Veterans Affairs Cooperative Study of Corticosteroids in Systemic Sepsis. PATIENTS: The septic population consisted of 1505 patients with evaluable data from the screening log of the Cooperative Study of Corticosteroids in Systemic Sepsis. All 91830 nonpsychiatric, noninfected patients discharged from the participating medical centers between October 1, 1984, and September 30, 1985, were included in the control population. MAIN OUTCOME MEASURE: Death through 8 years after the index hospitalization.
RESULTS: On the basis of a proportional hazards model constructed from the demographic and illness characteristics of the control population, the septic population was at significant risk of dying of nonseptic causes (26% predicted 1-year mortality). In the septic population, the daily risk of dying exceeded predictions from this model for 5 years, and the hazard rate rose with increasing severity of the septic episode throughout the first year (P<.05). Among 30-day survivors, sepsis reduced the remaining mean life span from a predicted 8.03 years to 4.08 years.
CONCLUSIONS: Sepsis not only causes deaths acutely, but also increases the risk of death for up to 5 years after the septic episode even after comorbidities are accounted for. The risk of late death during the first year is associated with the severity of the septic episode.

Entities:  

Mesh:

Year:  1997        PMID: 9091694

Source DB:  PubMed          Journal:  JAMA        ISSN: 0098-7484            Impact factor:   56.272


  123 in total

Review 1.  How do you choose antibiotic treatment?

Authors:  L Leibovici; I Shraga; S Andreassen
Journal:  BMJ       Date:  1999-06-12

Review 2.  Mobilization in severe sepsis: an integrative review.

Authors:  Sushant Govindan; Theodore J Iwashyna; Andrew Odden; Scott A Flanders; Vineet Chopra
Journal:  J Hosp Med       Date:  2015-01       Impact factor: 2.960

3.  Septic mice are susceptible to pulmonary aspergillosis.

Authors:  Claudia F Benjamim; Cory M Hogaboam; Nicholas W Lukacs; Steven L Kunkel
Journal:  Am J Pathol       Date:  2003-12       Impact factor: 4.307

4.  Surviving intensive care: a report from the 2002 Brussels Roundtable.

Authors:  Derek C Angus; Jean Carlet
Journal:  Intensive Care Med       Date:  2003-01-21       Impact factor: 17.440

Review 5.  A historical perspective on sepsis.

Authors:  Peter A Ward; Markus Bosmann
Journal:  Am J Pathol       Date:  2012-05-26       Impact factor: 4.307

Review 6.  Epigenetic regulation of immune cell functions during post-septic immunosuppression.

Authors:  William F Carson; Karen A Cavassani; Yali Dou; Steven L Kunkel
Journal:  Epigenetics       Date:  2011-03-01       Impact factor: 4.528

7.  Population burden of long-term survivorship after severe sepsis in older Americans.

Authors:  Theodore J Iwashyna; Colin R Cooke; Hannah Wunsch; Jeremy M Kahn
Journal:  J Am Geriatr Soc       Date:  2012-05-29       Impact factor: 5.562

8.  Disseminated Intravascular Coagulation Is an Independent Predictor of Adverse Outcomes in Children in the Emergency Department with Suspected Sepsis.

Authors:  Leonora R Slatnick; Dianne Thornhill; Sara J Deakyne Davies; James B Ford; Halden F Scott; Marilyn J Manco-Johnson; Beth Boulden Warren
Journal:  J Pediatr       Date:  2020-06-14       Impact factor: 4.406

9.  Surviving sepsis-but for how long?

Authors:  Peter Dodek
Journal:  Intensive Care Med       Date:  2005-01-28       Impact factor: 17.440

10.  New approaches to sepsis: molecular diagnostics and biomarkers.

Authors:  Konrad Reinhart; Michael Bauer; Niels C Riedemann; Christiane S Hartog
Journal:  Clin Microbiol Rev       Date:  2012-10       Impact factor: 26.132

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.